Publication | Open Access

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Clinical ImmunologyDose-escalation StudyTumor ImmunologyCancer ImmunosurveillanceMedicineImmunologySolid TumoursPathologyImmune Checkpoint InhibitorFirst-in-human Phase 1ImmunotherapyOncologyCancer ResearchImmunological Biomarkers